Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

New obesity jab that sparked diabetes row in US could get NHS green light

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

The Independent UK

Eli Lilly Stock Doesn't Have To Shoot Higher For Profits

If Eli Lilly stays around 440, this calendar spread profits on its neutral outlook.

Investors Business Daily

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says.

Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The Conversation

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

The New Daily

Dow Jones Falls On Peak-Rate Uncertainty; QCOM Falls While ETSY, RUN Rise After Earnings

The Dow Jones rose ahead of a Fed rate hike. Fed Chief Powell's comments suggested a rate pause. Eli Lilly surged after reporting a breakthrough Alzheimer's treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

'Remarkable' Alzheimer's drug reduces cognitive decline, study shows

Washington (AFP) - US pharmaceutical giant Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts despite some patients experiencing serious side effects.

AFP

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

Evening Standard

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The National (Scotland)

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

The Independent UK

'Remarkable' Alzheimer drug reduces cognitive decline, results show

Washington (AFP) - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts.

AFP

Eli Lilly Hits A Record-Smashing $409 Billion Market Cap Following Its Alzheimer's Win

Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.

Investors Business Daily

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug found

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

The Independent UK

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Dow Jones Futures: Fed Hike Due, PacWest, AMD In Focus. Eli Lilly Drug Slows Alzheimer's.

Another rate hike is expected today, but Fed guidance will be key. PacWest rebounded while AMD tumbled. Eli Lilly jumped on its Alzheimer's drug.

The Street

Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial

"This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline," Eli Lilly said.

Investors Business Daily

Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?

Industry analysts warn that a groundbreaking change in how Medicare buys drugs threatens industry growth, profits — and maybe patient care.

Daily Record

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

Barchart

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Investors Business Daily

Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates

Eli Lilly stock surged Thursday after diabetes drug Mounjaro blew past sales projections and led to promising weight loss in a Phase 3 study.

WEKU

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

Investors Business Daily

Dow Jones Futures Rise: Meta Soars, Drug Giants Climb, Specialty Chip Plays Dive

Futures: Meta Platforms boomed on earnings, but megacap techs can't hide broad market rally weakness. First Republic dived again.

Investors Business Daily

Novo Nordisk Sinks As Eli Lilly Plots Its Showdown In Obesity

Novo Nordisk stock dipped Monday after Eli Lilly posted the details of its study comparing Mounjaro and Wegovy in obesity treatment.

The Street

Jim Cramer Bluntly Schools Stock-Buyers On 3 'Amazing American' Companies

The CNBC host offers some pointed thoughts.

1 … 16 17 18 19

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations